Clinical Trial Detail

NCT ID NCT01776008
Title Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor negative breast cancer

Therapies

Goserelin + MK2206

Age Groups: adult

Additional content available in CKB BOOST